MedTrace Logo

Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung

NCT05228795 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-02-08

No results posted yet for this study

Summary

Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases. Malignant mesothelioma is an aggressive neoplasm that arises from mesothelial cells which form the lining of the pleural. There is a strong resemblance between epithelioid mesothelioma and lung adenocarcinoma, some of peripheral lung adenocarcinoma or SCC present with pleurotropic growth like mesothelioma. Glypican-1 (GPC1) is one the six glypican family members. It is one of cell surface heparan sulfate proteoglycans that acts as a growth factor signaling. The aim of this study is to evaluate the immunohistochemical expression of Glypican-1 in pleural epitheloid mesothelioma, lung adenocarcinoma and lung SCC

Conditions

  • Lung Cancer Adenocarcinoma
  • Lung Cancer Squamous Cell
  • Mesothelioma; Lung

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Nagwa Ahmed, Lecturer · Sohag University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-06-01
Completion
2022-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05228795 on ClinicalTrials.gov